Satipharm’s CBD Capsules
Satipharm AG is a Swiss firm specializing in developing medical cannabis brands leveraging its oral delivery technologies. The company’s flagship Gelpell-CBD Microgel Capsules are available in either 10mg, 50mg, or 100mg doses of cannabidiol (“CBD”) and available in a growing number of markets around the world. The established legal status of CBD means that these products can be sold in a wide array of markets that are off limits to THC-based brands.
The capsules are produced with cannabis extracts from its partner — AI FAME GMBH / Ai LABS SWISS AG — and fulfills all criteria of the European Pharmacopoeia with 92% purified CBD and no THC or other cannabinoids. Once extracted, the cannabinoids are processed under an exclusive technology use agreement by Gelpell AG, which substantially enhances the bioavailability of the cannabinoids after consumption. Bioavailability is one of the vexing issues surrounding cannabinoid therapies as the active ingredients are degraded by metabolic processes in the body. Gelpell’s micro-bead technology ensures delivery and dose accuracy under these conditions.
These capsules are available over-the-counter and are being used in two separate Phase 2 clinical trials being conducted through PhytoTech Therapeutics. The company also received approval for the manufacturing of THC-based products in Switzerland with the goal of developing new formulations to offer medical cannabis patients in Canada and Australia by the first half of next year — opening the door to even more opportunity.
Expanding Presence in Europe
Satipharm announced earlier this year that its Gelpell-CBD Microgel Capsules were available in all pharmacies throughout Germany. The company also announced that it signed a letter of intent with a leading pharmaceutical distributor and retailer in Denmark for distribution throughout Scandinavia. The company anticipates that the partnership will provide direct access to hundreds of thousands of potential customers through targeted campaigns.
More recently, the company announced that it received a “Free Sale Certificate” from German authorities that reduces constraints for international exports and removes regulatory trading impediments with other EU jurisdictions. The company’s CBD capsules are considered a “food supplement”, which makes it the only company in Europe with a GMP-grade nutraceutical CBD product. Management expects to see an increase in demand across Europe as a result.
The company has also been actively expanding its distribution network with a focus on Germany, Denmark, the UK, Ireland, the Netherlands, Spain, and Austria. In these countries, the company’s CBD capsules are available in several online shops, on Amazon, in mail order pharmacies, and in conventional brick-and-mortar pharmacies. Sales have started to rise in the months following the expansion with “sizable contracts” already in place.
Satipharm has successfully developed several key marketing channels throughout Europe and Australia. With United Greeneries applying to become a licensed dealer Harvest One could soon expand into Canada as well. The approval of United Greeneries as a licensed dealer could similarly enable it to access international markets through relationships that Satipharm has built over the past several years.
Please follow the link to read the full article: http://www.cannabisfn.com/licensed-producers-going-global-one-stands/
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/
- CFN Media
CanBud Distribution Corporation Closes 2M Second and Final Tranche of its Oversubscribed Private Placement Offering
CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).
The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.
Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands
In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.